Prognostic factors for patients treated with abiraterone

Autor: Cecília M Alvim, André Mansinho, Rita S Paiva, Raquel Brás, Patrícia M Semedo, Soraia Lobo-Martins, Carolina B da Ponte, Daniela Macedo, Leonor Ribeiro, José P dos Reis, Isabel Fernandes, Luís Costa

Publikováno v: Future Science OA, Vol 6, Iss 2 (2020)

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abi

Externí odkaz: https://doaj.org/article/9b77c19a88724e4bb03645e31d8bf5d9

Prognostic factors for patients treated with abiraterone

Autor: Daniela Macedo, Luis Costa, Isabel Fernandes, André Mansinho, R. Paiva, Leonor Ribeiro, C. Alvim, Carolina Borges da Ponte, José Palma dos Reis, R. Brás, Soraia Lobo-Martins, P. Semedo

Publikováno v: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Future Science OA

© Cecilia Melo Alvim. This work is licensed under the Creative Commons Attribution4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Aim: To evaluate prostate-specific antigen response (PSAr) defined

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c048882a38a870e219ce85955a75cce8
https://doi.org/10.2144/fsoa-2019-0079

Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel

Autor: Toshiaki Shinojima, Takeo Kosaka, Shinya Morita, Mototsugu Oya

Publikováno v: Cancer Science

The present study aimed to evaluate the efficacy of cabazitaxel in Japanese patients affected by metastatic castration‐resistant prostate cancer (mCRPC) previously treated with a docetaxel‐containing regimen. In this retrospective study, 41 patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::776bafd33b6d2b9b15dbd08ae5234f69
https://doi.org/10.1111/cas.13556

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer:1- and 2-Year Open-label Follow-up Results

Autor: Per Rathenborg, Edwina Baskin-Bey, Axel Heidenreich, Matthew R. Smith, Bertrand Tombal, Johan Braeckman, Mohammad Hirmand, Jiri Heracek, Peter Iversen, Patrick Werbrouck, Taoufik Ouatas, Michael Borre, Hendrik Van Poppel, Frank Perabo, Benoit Baron, De Phung

Publikováno v: Tombal, B, Borre, M, Rathenborg, P, Werbrouck, P, Van Poppel, H, Heidenreich, A, Iversen, P, Braeckman, J, Heracek, J, Baskin-Bey, E, Ouatas, T, Perabo, F, Phung, D, Baron, B, Hirmand, M & Smith, M R 2015, ' Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer : 1-and 2-Year Open-label Follow-up Results ', European Urology, vol. 68, no. 5, pp. 787–794 . https://doi.org/10.1016/j.eururo.2015.01.027
European urology 68(5), 787-794 (2015). doi:10.1016/j.eururo.2015.01.027

BACKGROUND: Enzalutamide is an androgen receptor inhibitor with a demonstrated overall survival benefit in metastatic castration-resistant prostate cancer. A phase 2 study of enzalutamide monotherapy in patients with hormone-naïve prostate cancer (H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c26cf6f82ac511b0bbfed4231b5ff63
https://pure.au.dk/portal/da/publications/longterm-efficacy-and-safety-of-enzalutamide-monotherapy-in-hormonenaive-prostate-cancer(a75c269b-762d-40e6-909d-1d16cc684507).html